Doctors call for clarity amid opposing AstraZeneca vaccine views
Health authorities in European Union (EU) countries have intervened amid concerns around the safety of the AstraZeneca (LSE: AZN) COVID-19 vaccine.
Denmark has temporarily stopped using the vaccine, developed by the Anglo-Swedish drugmaker along with the University of Oxford, following reports of a small number of blood clots and one death.
"Information available so far indicates that the number of thromboembolic events in vaccinated people is no higher than that seen in the general population"It is not yet known whether these episodes were linked to the vaccine, a batch of which has also been suspended from usage in Austria after a person was diagnosed with multiple thrombosis and died 10 days after vaccination, and another recipient was hospitalized with pulmonary embolism.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze